中国神经再生研究(英文版) ›› 2025, Vol. 20 ›› Issue (9): 2598-2610.doi: 10.4103/NRR.NRR-D-23-01348

• 原著:脑损伤修复保护与再生 • 上一篇    下一篇

缺血性脑卒中后认知障碍的潜在生物标志物: 血清磷酸化α-突触核蛋白

  

  • 出版日期:2025-09-15 发布日期:2024-12-29

Decreased levels of phosphorylated synuclein in plasma are correlated with poststroke cognitive impairment

Yi Wang1, #, Yuning Li2, #, Yakun Gu2, #, Wei Ma2 , Yuying Guan2, 3, Mengyuan Guo2 , Qianqian Shao2 , Xunming Ji2, 3, Jia Liu2, *   

  1. 1 Department of Clinical Laboratory, Beijing Bo’ai Hospital, China Rehabilitation Research Center, Capital Medical University, Beijing, China;  2 Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Beijing Advanced Innovation Center for Big Data-based Precision Medicine, Capital Medical University, Beijing, China;  3 Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China
  • Online:2025-09-15 Published:2024-12-29
  • Contact: Jia Liu, PhD, liujia_19901005@163.com.
  • Supported by:
    This research was supported by the Scientific Research Project of China Rehabilitation Research Center, No. 2021zx-23; the National Natural Science Foundation of China, No. 32100925; and the Beijing Nova Program, No. Z211100002121038.

摘要:

脑卒中后认知功能障碍是许多缺血性脑卒中患者的主要继发性损伤之一,但该疾病的早期诊断和干预仍然存在困难。实验旨在探讨α-突触核蛋白在缺血性脑卒中后认知障碍中的特殊作用和验证血清磷酸化α-突触核蛋白水平是否可以作为该疾病的生物标志物。缺血性脑卒中模型小鼠脑梗死区周围和慢性缺氧小鼠脑中,α-突触核蛋白均发生磷酸化和病理性聚集。这表明缺氧是导致缺血性脑卒中小鼠脑中α-突触核蛋白病理变化的内在原因。缺血性脑卒中患者血清中磷酸化α-突触核蛋白水平明显低于正常人,且与缺血性脑卒中患者的认知水平呈正相关,且缺血性脑卒中患者血清中磷酸化α-突触核蛋白的水平与高密度脂蛋白呈正相关。虽然缺血性脑卒中模型小鼠在术后14天内并未出现明显的认知功能障碍和脂质代谢障碍,但部分小鼠的认知功能随着磷酸化α-突触核蛋白水平的降低而下降。这些结果表明,血清中的磷酸化α-突触核蛋白具有成为缺血性脑卒中后认知功能障碍的生物标志物的潜在可能性。

https://orcid.org/0000-0001-6711-3841 (Jia Liu)

Abstract: Poststroke cognitive impairment is a major secondary effect of ischemic stroke in many patients; however, few options are available for the early diagnosis and treatment of this condition. The aims of this study were to (1) determine the specific relationship between hypoxic and α-synuclein during the occur of poststroke cognitive impairment and (2) assess whether the serum phosphorylated α-synuclein level can be used as a biomarker for poststroke cognitive impairment. We found that the phosphorylated α-synuclein level was significantly increased and showed pathological aggregation around the cerebral infarct area in a mouse model of ischemic stroke. In addition, neuronal α-synuclein phosphorylation and aggregation were observed in the brain tissue of mice subjected to chronic hypoxia, suggesting that hypoxia is the underlying cause of α-synuclein-mediated pathology in the brains of mice with ischemic stroke. Serum phosphorylated α-synuclein levels in patients with ischemic stroke were significantly lower than those in healthy subjects, and were positively correlated with cognition levels in patients with ischemic stroke. Furthermore, a decrease in serum high-density lipoprotein levels in stroke patients was significantly correlated with a decrease in phosphorylated α-synuclein levels. Although ischemic stroke mice did not show significant cognitive impairment or disrupted lipid metabolism 14 days after injury, some of them exhibited decreased cognitive function and reduced phosphorylated α-synuclein levels. Taken together, our results suggest that serum phosphorylated α-synuclein is a potential biomarker for poststroke cognitive impairment.

Key words: biomarker,  high-density lipoprotein,  ischemic stroke,  phosphorylated α-synuclein,  poststroke cognitive impairment